These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 29550245)

  • 21. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group.
    Verweij J; Lee SM; Ruka W; Buesa J; Coleman R; van Hoessel R; Seynaeve C; di Paola ED; van Glabbeke M; Tonelli D; Judson IR
    J Clin Oncol; 2000 May; 18(10):2081-6. PubMed ID: 10811673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
    Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
    Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
    Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Bramwell V; Rouesse J; Steward W; Santoro A; Schraffordt-Koops H; Buesa J; Ruka W; Priario J; Wagener T; Burgers M
    J Clin Oncol; 1994 Jun; 12(6):1137-49. PubMed ID: 8201375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
    Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
    J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    Bupathi M; Hays JL; Chen JL
    PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.
    Demetri GD; Le Cesne A; Chawla SP; Brodowicz T; Maki RG; Bach BA; Smethurst DP; Bray S; Hei YJ; Blay JY
    Eur J Cancer; 2012 Mar; 48(4):547-63. PubMed ID: 22240283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
    Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
    Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
    Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
    Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
    Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.
    Bui-Nguyen B; Butrynski JE; Penel N; Blay JY; Isambert N; Milhem M; Kerst JM; Reyners AK; Litière S; Marréaud S; Collin F; van der Graaf WT;
    Eur J Cancer; 2015 Jul; 51(10):1312-20. PubMed ID: 25912752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO).
    Schmitt T; Mayer-Steinacker R; Mayer F; Grünwald V; Schütte J; Hartmann JT; Kasper B; Hüsing J; Hajda J; Ottawa G; Mechtersheimer G; Mikus G; Burhenne J; Lehmann L; Heilig CE; Ho AD; Egerer G
    Eur J Cancer; 2016 Sep; 64():74-82. PubMed ID: 27367154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
    Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
    Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
    Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
    J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.